Abstract-Hypertension is a risk factor for cardiovascular disease. Increased urinary sodium excretion, representing dietary sodium intake, is associated with hypertension. Low sodium intake has been associated with increased mortality in observational studies. Further studies should assess whether confounding relationships explain associations between sodium intake and outcomes. We studied UK Biobank participants (n=457 484; mean age, 56.3 years; 44.7% men) with urinary electrolytes and blood pressure data. Estimated daily urinary sodium excretion was calculated using Kawasaki formulae. We analyzed associations between sodium excretion and blood pressure in subjects without cardiovascular disease, treated hypertension, or diabetes mellitus at baseline (n=322 624). We tested relationships between sodium excretion, incidence of fatal and nonfatal cardiovascular disease, heart failure, and mortality. Subjects in higher quintiles of sodium excretion were younger, with more men and higher body mass index. There was a linear relationship between increasing urinary sodium excretion and blood pressure. During median follow-up of 6.99 years, there were 11 932 deaths (1125 cardiovascular deaths) with 10 717 nonfatal cardiovascular events. There was no relationship between quintile of sodium excretion and outcomes. These relationships were unchanged after adjustment for comorbidity or excluding subjects with events during the first 2 years follow-up. No differing risk of incident heart failure (1174 events) existed across sodium excretion quintiles. Urinary sodium excretion correlates with elevated blood pressure in subjects at low cardiovascular risk. No pattern of increased cardiovascular disease, heart failure, or mortality risk was demonstrated with either high or low sodium intake.
H ypertension is a modifiable risk factor for development of cardiovascular disease (CVD)-the leading cause of death in high income countries. 1, 2 Large cohort studies showed associations between high sodium consumption and raised blood pressure. [3] [4] [5] Clinical trials have demonstrated that reduction in sodium intake leads to lowering of blood pressure, [6] [7] [8] and international guidelines advocate a dietary sodium intake of 1.5 to 2.4 g per day. 9 However, observational cohort studies (in ≈3600 to 102 000 participants) consistently demonstrate J-shaped relationships between sodium intake and CVD risk whereby low sodium intake is associated with higher cardiovascular risk. [10] [11] [12] In the Prospective Urban Rural Epidemiology study (n=101 945), both low (<3 g/day) and high (>6 g/day) sodium intakes were associated with higher risk of CVD. Some observational data controversially suggest that salt intake relates positively to life expectancy. 13 Thus, conventional dietary guidance on reduction of sodium intake conflicts with observational population data regarding CVD risk, even after correction for baseline CVD, blood pressure, and cholesterol. 10 One explanation often proposed is of "reverse causality" where subjects with comorbid conditions (eg, hypertension and heart failure) have low sodium intake either as recommended therapy or are malnourished because of poor dietary (and sodium) intake. This explanation becomes less robust in large cohort studies using appropriate statistical analysis to account for comorbidities and baseline individual cardiovascular risk profile. 3, 10, 14 We aimed to test whether reverse causality accounted for J-shaped relationships between sodium intake and CVD or mortality.
Materials and Methods
UK Biobank data are available on application to the UK Biobank for data access (http://www.ukbiobank.ac.uk/), and authors have returned derived data to UK Biobank as per their requirements. Between April 2007 and December 2010, over 500 000 participants were recruited by UK Biobank and had baseline measurements recorded at 1 of 22 assessment centers in Scotland, England, or Wales, as described elsewhere. 15 UK Biobank received ethical approval from the North West Multi-Center Research Ethics Committee (REC reference: 11/ NW/03820). All participants gave written informed consent before enrollment, which was conducted in accord with the principles of the Declaration of Helsinki.
Ethnicity was coded as white, South Asian, black, or other, with white used as the referent group. Body mass index (BMI) was calculated as weight (kg)/height2 (m). Smoking status was selfreported and categorized as never, former, or current smoker, and area-based sociodemographic status was derived from postcode of residence, using Townsend score, 16 where higher scores relate to greater deprivation. Diagnosis by a doctor of diabetes mellitus (DM), stroke, myocardial infarction, transient ischemic attack, or brain hemorrhage was self-reported at baseline. Family history of CVD (stroke or heart disease in participant's mother, father, or sibling) was self-reported.
A midstream urine sample collected was refrigerated between 2 and 8°C until potentiometric measurement for sodium and potassium content using a Beckman Coulter, Ltd (United Kingdom), AU5400 analyzer. Sodium and potassium concentrations (in mmol/L) were capped at sex-specific mean ±4 SDs. Kawasaki formulae 17 were used to convert spot sodium and potassium measurements into estimated 24-hour excretion (eNa 24h and eK 24h , in g/day). Two resting blood pressure measurements were taken, according to a standard operating procedure (http:// biobank.ctsu.ox.ac.uk/showcase/docs/Bloodpressure.pdf) at least 1 minute apart, by trained staff, using either an automated sphygmomanometer with an appropriate cuff size relative to the participant's arm or manually if an automated reading was not possible. Mean systolic and diastolic blood pressures were calculated and used to derive an estimated mean arterial blood pressure (MABP); MABP=(systolic blood pressure+2×diastolic blood pressure)/3, and pulse pressure=(systolic blood pressure−diastolic blood pressure). Lean body mass as fat-free mass was derived from wholebody bioimpedance measures using the Tanita BC418MA body composition analyzer. For full data collection protocols, refer to UK Biobank online (http://www.ukbiobank.ac.uk).
The process for generation of the cohort for analysis is shown in Figure S1 in the online-only Data Supplement. Charlson comorbidity index was calculated for all subjects, 18 and a secondary analysis was conducted after excluding those participants with Charlson score >0. Use of diuretics and blood pressure medications were detected by searching medicines reported by participants in the 63rd revision of the British National Formulary.
CVD events (myocardial infarction, stroke, heart failure admission International Classification of Diseases, Tenth Revision, codes I20-23, I24.1, I25.2, I60, I61, I62, I63, or I64) were identified by linkage with routine hospital data, and date and cause of death (where appropriate) were obtained from death certificates held by the National Health Service Information Centre for participants from England and Wales and the National Health Service Central Register Scotland for participants from Scotland. All-cause mortality (ACM) was defined as death from all causes. Start of follow-up was date of assessment, and end of follow-up for mortality end points was recorded as the end of data collection for the assessment center attended (November 30, 2015, for centers in Scotland; January 31, 2016, for centers in England/Wales), or date of death, whichever came first. For nonfatal outcomes, end of follow-up was date of death, first date of hospitalization for nonfatal CVD, or end of follow-up.
Statistical Analyses
We excluded participants hospitalized within 30 
Blood Pressure Models
Associations of MABP with sex-specific quintiles of eNa 24h were examined using sex-specific unadjusted linear regression models. Each model was then adjusted for the following; age, lean body mass, ethnicity, family history of CVD, smoking status, eK 24h , and deprivation score. Linearity of associations was further explored using restricted cubic splines (data not shown).
CVD Models
Associations of fatal or nonfatal CVD or ACM with eNa 24h were examined using eNa 24h in sex-specific quintiles in Cox proportional hazard models. In these main analyses, we excluded those with treated hypertension, baseline CVD, or baseline DM ( Figure S1 ). All models were adjusted for age, Townsend deprivation index, eK 24h , MABP (used as continuous variable), smoking status, ethnicity, lean body mass, family history of CVD, rheumatoid arthritis, atrial fibrillation, and a binary variable for Charlson comorbidity score >0. We checked for effect mediation by MABP through models that did not adjust for this variable. The proportional hazard assumption was checked by visual inspection of Schöenfeld residuals.
To minimize effect of reverse causality on predictors of early CVD events, we performed additional landmark sensitivity analyses, analyzing events occurring after 2 years follow-up. Further sensitivity analyses were conducted excluding participants with Charlson comorbidity index of >0.
Incident heart failure was treated as specific event of interest, on the basis that excess sodium ingestion may lead to sodium and water retention triggering heart failure. Cox proportional hazard models were used to test for associations with eNa 24h quintiles, using the methods as for other CVD events.
All analyses were performed using STATA 14 (StataCorp LP, College Station). A P of <0.05 was considered statistically significant.
Results

Baseline Demographics, Blood Pressure, and Urinary Sodium Excretion in All Subjects and Those Without Comorbid Disease
Baseline characteristics for all subjects categorized by quintile of MABP are shown in Table 1 . Subjects in the highest MABP quintiles were more likely to be older, have greater BMI and lean body mass, a higher prevalence of family history of CVD, less likely to have a positive smoking history, reside in an area of greater socioeconomic deprivation, and have greater eNa 24h excretion. When categorized by quintiles of eNa 24h excretion (Table 2) , subjects in the highest eNa 24h quintiles were younger, had higher BMI and lean body mass, lower prevalence of family history of CVD, lower smoking prevalence, more likely to reside in areas of lower socioeconomic deprivation, and have higher MABP. Excluding those with treated hypertension, baseline CVD, or DM did not substantially attenuate these results (Tables S1 and S2 ). In regression models assessing relationships between eNa 24h and MABP performed in subjects without CVD, DM, or treated hypertension, there were linear relationships between increasing quintiles of eNa 24h and increased MABP in both women and men (Figure 1 ). These associations were consistent before and after adjustment for baseline characteristics and were similar when restricted to subjects with Charlson score of zero to minimize influence of residual confounding. There was no association between quintiles of eNa 24h and risk of CVD events or ACM in any model (Figure 2 ). These relationships were unaffected by adjustment for self-reported Adjusted hazard ratios of sex-specific quintiles of eNa 24h on the risk of all-cause mortality and fatal or nonfatal cardiovascular disease events. Allcause mortality is shown in upper panels (A and B) and nonfatal cardiovascular disease events in lower panels (C and D) . Analyses are for all participants (A and C; n=322 624) and excluding participants with a Charlson score of >0 (B and D; n=160 920). All plots exclude participants with baseline cardiovascular disease, diabetes mellitus, or treated hypertension. Na24h Quintiles represent quintile of eNa 24h as per Table 2 .
chronic kidney disease or statin use ( Figure S2 ). These relationships did not change either after limiting the adjustment model to not include MABP as a potential effect mediator, or following landmark analysis excluding subjects who died within 2 years of follow-up, or after substituting lean body mass with conventional BMI ( Figure S3 ). Data on the incidence of subtypes of CVD (myocardial infarction, ischemic stroke, and hemorrhagic stroke) are shown in Table S3 and Figure S4 . There were 283 incident heart failure hospitalizations during follow-up in the 322 624 participants without baseline CVD, DM, or treated hypertension. There were no statistically significant differences in risk of incident heart failure across eNa 24h quintiles in either men or women ( Figure 3 ).
Discussion
In a large prospective cohort study, we demonstrate a consistent relationship between estimated urinary sodium excretion as a marker of sodium intake and elevation in blood pressure. These relationships were present both in the whole cohort and when restricted to subjects free of baseline comorbidity, specified by restricting analysis to those without baseline CVD, DM, or treated hypertension and with Charlson comorbidity score of zero. These findings are consistent with other cohort studies, interventional clinical trials, and meta-analyses.
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The mechanisms by which dietary sodium contributes to raised blood pressure have been reviewed extensively elsewhere. 19 Sodium excess has been associated with excess activation of the sympathetic nervous system, increased vascular tone, and endothelial dysfunction, as well as end organ damage with left ventricular hypertrophy, glomerulosclerosis, and arteriolosclerosis. In industrialized countries, diets rich in sodium and low in potassium are the norm. Processed meals are rich in sodium. Societies following a nonindustrialized diet low in sodium have low prevalence (<1%) of hypertension. [20] [21] [22] Meta-analyses demonstrate that reduction in dietary sodium intake is associated with average reduction in systolic blood pressure of 3 to 5.4 mm Hg in hypertensive subjects. 7, 8 Our data add weight to the hypothesis that reduction of dietary sodium intake may lead to lower blood pressure. Unfortunately, we do not have long-term blood pressure changes to assess the influence of sodium intake on development of hypertension.
The relationship between sodium excretion and future nonfatal CVD and ACM is more complex and essentially showed no strong relationship between higher or lower sodium intake with risk of mortality or CVD. These null relationships did not appear to be altered by adjustment for comorbid disease using the Charlson comorbidity index. The landmark analysis excluding subjects who died within 2 years of follow-up showed similar lack of a relationship between sodium excretion and risk of CVD death. This refutes the perception that reverse causality underpins relationships whereby those with the lowest sodium intake have greater mortality risk because of underlying (perhaps undiagnosed) disease.
Our results demonstrating a lack of straightforward linear relationships between high sodium intake and increased risk of mortality of CVD are broadly in keeping with other studies. Although much public policy and conventional advice focuses on benefits of reduction of sodium intake on future cardiovascular health, large cohort studies, including subjects with comorbidities associated with increased CVD risk, such as chronic kidney disease and DM, have demonstrated there is a nadir of sodium consumption below which increased risk of future CVD or ACM increases. 12, [23] [24] [25] [26] [27] Alternatively, lower sodium intake may risk via activation of the renin-angiotensin-aldosterone system to maintain sodium and water homeostasis exposing the cardiovascular system to the deleterious effects of aldosterone. 28 As heart failure represents a syndrome of renal salt avidity driving fluid retention, in the setting of cardiac dysfunction, 29 we specifically analyzed the influence of sodium intake on incidence of heart failure hospitalization. However, we could find no evidence that sodium excretion as a marker for sodium intake was associated with incident heart failure, albeit in a small number of events. Alternatively, if renal sodium avidity was expected to be a driver for future heart failure, one might expect lower sodium excretion to precede future heart failure events, but this was not the case. Unlike Prospective Urban Rural Epidemiology, we do not demonstrate any association with low sodium excretion on CVD events or ACM supporting the notion that public health policy reducing sodium intake in healthy individuals is not harmful and will be associated with reduced blood pressure. It may take longer follow-up than this study to demonstrate the benefits of sodium reduction on CVD events in low-risk individuals.
Only a large randomized trial of differing sodium intake targets will address what the optimal sodium intake should be in an industrialized nation. In the face of public health advice, competing pressures from the food industry, and trends toward a diet based on convenience foods, such a trial would be challenging to implement and would require regular monitoring to ensure participants complied with the prescribed sodium intake. Experts have designated this such a pressing issue that undertaking such a trial in institutionalized environments such as prisons may be justified. 30 There are limitations to this study. The population recruited to UK Biobank were volunteers and, therefore, may not be representative of older or more comorbid populations. As observational data, we describe associations and cannot infer causal relationships. We used the Kawasaki formula to estimate daily sodium excretion. Estimating sodium excretion Figure 3 . Adjusted hazard ratios of sex-specific quintiles of eNa 24h on incident heart failure in 322 624 UK Biobank participants, excluding those with baseline cardiovascular disease, diabetes mellitus, or treated hypertension. Na24h Quintiles represent quintile of eNa 24h as per Table 2 .
from a single urine sample may be inaccurate. We chose to use the Kawasaki formula to allow comparability between studies because it is felt to be the least biased of a number of estimation algorithms for estimating 24-hour sodium excretion. 31 The relationship between sodium and fatal and nonfatal CVD was not in keeping with perceived wisdom that lower sodium intake leads to lower risk of CVD. Sodium intake was linearly associated with blood pressure, reducing the probability that exposure misclassification biased results to the null. The absence of serum biochemistry is limitation although out with electrolyte disorders, serum sodium is homeostatically maintained in a physiological range in the face of a wide dietary intake. There was no assessment of salt sensitivity in this study, which would provide more detailed insight into which groups are at greater risk from increased dietary salt intake. 32 Finally, recent sodium balance studies demonstrate that relationships between dietary sodium intake and urinary excretion are not as simple as previously thought with cyclical handling of sodium over several days and sequestering of sodium in organs such as skin and muscle. [33] [34] [35] [36] Although this opens new paradigms of thought on sodium homeostasis, for large cohort epidemiological research, using estimates of sodium intake and excretion from spot urine and derivation from sodium:creatinine ratio is widely accepted.
10,17
Perspectives
In summary, we confirm the relationship between increasing sodium intake and blood pressure is linear, but there is a fairly limited relationship between salt intake and risk of fatal/nonfatal CVD and ACM in subjects at low cardiovascular risk. Based on these observational data from a large cohort, we demonstrate no strong association of high or low sodium excretion, as a marker of dietary salt intake, with increased risk of cardiovascular events or death. These data may further inform public health debate around recommended dietary daily sodium intake.
